Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial

7 Apr 2025

Abstract excerpt

Large genomic programs have contributed to improving drug development in cancer. To assess the potential benefit of using larger gene panels to guide molecular-based treatments, we conducted a multicenter randomized trial in patients with advanced and/or metastatic solid cancer. Molecular alterations were determined using either a panel of 324 cancer-related genes (Foundation OneCDX (F1CDX)) or a limited panel of...

Source

Identifiers

PMID: 40195451
DOI: 10.1038/s41591-025-03613-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialPMID 40195451Read ↗

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read ↗

Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic options.Semantic proximity Read ↗

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsSemantic proximity Read ↗

First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.Semantic proximity Read ↗

Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced CancersSemantic proximity Read ↗

Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor boardSemantic proximity Read ↗

Whole-genome and transcriptome analysis enhances precision cancer treatment options.Semantic proximity Read ↗

Comparison of whole-exome, whole-transcriptome genomic profiling and targeted sequencing with 50-gene panels in advanced solid tumorsSemantic proximity Read ↗

Pragmatic Nationwide Master Observational Trial Based on Genomic Alterations in Advanced Solid Tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II Study Protocol KCSG AL-22-09Semantic proximity Read ↗

A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers.Semantic proximity Read ↗

Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.Semantic proximity Read ↗

Health Care Impact of Comprehensive Genomic Profiling of Solid Tumors in Patient Management Using POWER (Precision Oncology at Western University).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.